ISIN:FR0012333284

EQS-News: Abivax appoints Patrick Malloy as Senior Vice President Investor Relations

Retrieved on: 
Mercredi, août 23, 2023
Exercise, Person, CMC, Toxicity, Research, Document, EMA, Advertising, FDA, News, Risk management, Abivax

Words such as “expect,” "will" and variations of such words and similar expressions are intended to identify forward-looking statements.

Key Points: 
  • Words such as “expect,” "will" and variations of such words and similar expressions are intended to identify forward-looking statements.
  • Furthermore, these forward-looking statements, forecasts and estimates are only as of the date of this press release.
  • Abivax disclaims any obligation to update these forward-looking statements, forecasts or estimates to reflect any subsequent changes that the Company becomes aware of, except as required by law.
  • Persons into whose possession this document comes are required to inform themselves about and to observe any such restrictions.

EQS-News: Abivax secures up to EUR 150M from two structured debt financing transactions

Retrieved on: 
Mardi, août 22, 2023
Exercise, Chronicle of the Market Prices, Maxima and minima, The Heights, Common stock, USD, Ulcerative colitis, Market, EUR, Euronext Paris, UC, VWAP, Patient, Transaction, CEST, Convertible, MRO, Security (finance), Pharmaceutical industry, Credit, Bank, Commercial property, Life insurance, Abivax, KREO

The subsequent tranches of the Kreos / Claret Financing and the Heights Financing are subject to certain conditions, as further set forth below.

Key Points: 
  • The subsequent tranches of the Kreos / Claret Financing and the Heights Financing are subject to certain conditions, as further set forth below.
  • The Kreos / Claret Financing consists of three tranches of EUR 25,000,000 each in aggregate principal amount.
  • The convertible bonds, the non-convertible bonds and the warrants of the Kreos / Claret Financing will not be listed on any market.
  • Abivax is allowed to pre-pay the amounts due under the second and third tranches of the Kreos / Claret Financing any time.

EQS-News: Abivax announces plans to conduct registered public offering in the United States

Retrieved on: 
Jeudi, août 10, 2023
Form, Sale, American depositary receipt, Euronext Paris, CEST, Trinidad and Tobago Securities and Exchange Commission, Security (finance)

The issuer is solely responsible for the content of this announcement.

Key Points: 
  • The issuer is solely responsible for the content of this announcement.
  • PARIS, France, August 10, 2023 – 06:00 p.m. (CEST) – Abivax SA (Euronext Paris: FR0012333284 – ABVX) today announced that it plans to conduct a registered public offering of its ordinary shares, in the form of American Depositary Shares, in the United States, subject to market and other conditions, and has confidentially submitted a draft registration statement on Form F-1 to the U.S. Securities and Exchange Commission.
  • The timing, number of securities to be offered in the proposed offering and their price have not yet been determined.
  • This press release does not, and is not intended to, constitute an offer to sell or the solicitation of an offer to buy securities, and shall not constitute an offer, solicitation or sale in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of that jurisdiction.